Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Eukaryotic Gene Expression
Импакт фактор: 1.841 5-летний Импакт фактор: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN Печать: 1045-4403
ISSN Онлайн: 2162-6502

Выпуски:
Том 29, 2019 Том 28, 2018 Том 27, 2017 Том 26, 2016 Том 25, 2015 Том 24, 2014 Том 23, 2013 Том 22, 2012 Том 21, 2011 Том 20, 2010 Том 19, 2009 Том 18, 2008 Том 17, 2007 Том 16, 2006 Том 15, 2005 Том 14, 2004 Том 13, 2003 Том 12, 2002 Том 11, 2001 Том 10, 2000 Том 9, 1999 Том 8, 1998 Том 7, 1997 Том 6, 1996 Том 5, 1995 Том 4, 1994

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukarGeneExpr.v11.i1-3.50
44 pages

New Prospectives of Prostate Cancer Gene Therapy: Molecular Targets and Animal Models

Chia-Ling Hsieh
Departments of Urology, University of Virginia School of Medicine, Charlottesville, VA 22908
Leland W. K. Chung
Departments of Urology and Cell Biology, University of Virginia School of Medicine, Charlottesville, VA 22908

Краткое описание

Prostate cancer is the most common cancer and the second leading cause of cancer-related death among North American men. The low cure rate for prostate cancer is associated with the fact that many patients have metastatic disease at the time of disease presentation. Currently available therapeutic modalities for prostate cancer, such as surgery, radiation, hormone therapy, and chemotherapy, have failed to cure patients because these therapies are not sufficiently tumor-specific, resulting in dose-limiting toxicity. Therefore, gene therapy may offer great promise in this regard. In this article, we summarize current advances in gene therapy technologies for the treatment of cancer in general, and future prospects for treatment of human prostate cancer metastasis. We specifically emphasize current studies for improvement, both in the efficiency and the specificity of viral and nonviral vectors, and restricted transgene expression in tumors, to achieve selective targeting with minimized host organ toxicity, based on the molecular understanding of potential regulatory differences between normal and tumor cells. Cell and animal models used to study prostate cancer growth, invasion, and metastasis, and their usefulness in preclinical evaluation of therapeutic vectors in the treatment of protate cancer skeletal metastasis are also discussed.


Articles with similar content:

Current Perspectives on Novel Drug Carrier Systems and Therapies for Management of Pancreatic Cancer: An Updated Inclusive Review
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 3
Rohit R. Bhosale, Bannimath Gurupadayya, Devegowda Vishakante Gowda, Koganti Venkata Sairam, Riyaz Ali Mahafez Ali Osmani, Rudra Vaghela, Hosahalli Veerabhadrappa Gangadharappa, Parthasarathi Keshavarao Kulkarni
Critical Aspects in Rationale Design of Fluorouracil-Based Adjuvant Therapies for the Management of Colon Cancer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 2
Vivek Ranjan Sinha, Honey
From Molecular Tumor Diagnostics to Individualized Treatment with Phytochemicals Derived from Chinese Herbs
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Thomas Efferth
Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 3-4
Mengying Hong, Ren Sun, Jing Qian, Hongyu Deng, Shu Zheng, Kejun Tang, Yushen Du, Kefeng Ding, Musheng Zeng
Individual Response to Ionizing Radiation and Personalized Radiotherapy
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 1-2
Alex Philchenkov, Anna Dubrovska, Emiliya A. Domina